Search Results - Morcos, P.N.

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)

    3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC) by Barlesi, F, Dingemans, A.M.C, Ou, I, Ahn, J.S, Petris, L.D, Kim, D.W, Yang, J.C.H, Hughes, B, Lena, H, Moro-Sibilot, D, Bearz, A, Viteri, S, Mekhail, T, Spira, A, Zeaiter, A, Bordogna, W, Sturm, C, Golding, S, Morcos, P.N, Govindan, R

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    1180 RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO

    1180 RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO by Goelzer, P, Morcos, P.N, Tran, J.Q, Wen, B, Shulman, N, Smith, P, Singer, T, Brennan, B.J, Hammond, J

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA

    CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA by Dickinson, M.J., Morschhauser, F., Iacoboni, G., Carlo‐Stella, C., Offner, F.C., Sureda, A., Salles, G., Martinez, J., Crump, M., Thomas, D.N., Morcos, P.N., Ferlini, C., Broeske, A., Bacac, M., Dimier, N.J., Umaña, P., Moore, T., Weisser, M., Hutchings, M.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: